Government news, all in one place

Medicines and Healthcare products Regulatory Agency

Medicines and Healthcare products Regulatory Agency

The Medicines and Healthcare products Regulatory Agency (MHRA) is a UK government agency responsible for ensuring that medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy.

Communication Overview

Total releases

Number of press releases published by this department during the last 12 months, based on publicly available announcements.
1057

Avg per month

Average number of press releases published per calendar month over the last 12 months. This smooths short-term fluctuations in publishing activity.
12.6

Avg word count

Average length of published press releases, measured in words. Calculated only for months where content was published.
869

Avg readability

Average Flesch Reading Ease score across all published press releases. Higher values indicate plainer English. Scores are indicative only and vary by subject matter.
26.7

Friday PM releases

Percentage of press releases published after 3pm on Fridays, relative to the department’s total output during the period.
4.5%

Single-release items

Estimated proportion of announcements published once, without a closely related follow-up release during the same period. This is based on similarity of titles and timing.
100%
Metrics are descriptive only and indicate publication patterns rather than intent or impact.

Releases per month

Based on publicly published press releases (last 12 months)

874 articles

Showing 1-30

Yellow Cards: bad in football; brilliant in patient safety

Yellow Cards: bad in football; brilliant in patient safety

Friday, 10 July 2026

As football fans across the country get behind England, the MHRA wants to keep any Yellow Cards off the pitch – and instead let people know that Yello...

Read More → press_release
Heat, travel and late nights: How summer can affect your medicines and how to stay safe

Heat, travel and late nights: How summer can affect your medicines and how to stay safe

Thursday, 09 July 2026

The MHRA is urging people to “summer-proof your health” as warmer weather, travel, and changing routines can affect how medicines and medical devices ...

Read More → press_release
MHRA safety review gives UK plasma donations go ahead

MHRA safety review gives UK plasma donations go ahead

Thursday, 09 July 2026

Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of UK?donor plasma for five high?priority plasma-derived medicinal pro...

Read More → press_release
Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines

Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines

Wednesday, 08 July 2026

The MHRA’s Criminal Enforcement Unit dismantled a multimillion-pound criminal network responsible for illegally supplying medicines. ...

Read More → press_release
Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Wednesday, 08 July 2026

As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.??...

Read More → press_release
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer

Monday, 06 July 2026

Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that develops from Merkel cells, specialised neuroendocrine cells found in th...

Read More → press_release
Semaglutide (Wegovy) approved to treat form of liver disease

Semaglutide (Wegovy) approved to treat form of liver disease

Friday, 03 July 2026

The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis....

Read More → press_release
Making regulation a catalyst, not a barrier, for UK life sciences

Making regulation a catalyst, not a barrier, for UK life sciences

Thursday, 02 July 2026

MHRA CEO argues that for the UK’s long-term health and prosperity, regulation should help lead, rather than follow, innovation...

Read More → news_story
MHRA authorises gemcitabine delivery system for adults with BCG unresponsive high risk non muscle invasive bladder cancer

MHRA authorises gemcitabine delivery system for adults with BCG unresponsive high risk non muscle invasive bladder cancer

Wednesday, 01 July 2026

As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close ...

Read More → press_release
MHRA secures convictions after a decade long investigation into falsely marked baby feeding devices

MHRA secures convictions after a decade long investigation into falsely marked baby feeding devices

Wednesday, 01 July 2026

MHRA investigation secures fraud convictions linked to the supply of non-compliant medical devices....

Read More → press_release
Update on the PATHWAYS clinical trial

Update on the PATHWAYS clinical trial

Friday, 19 June 2026

As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants....

Read More → news_story
Warning on promoting newly licensed prescription only medicines and unlicensed medicines for weight management

Warning on promoting newly licensed prescription only medicines and unlicensed medicines for weight management

Thursday, 18 June 2026

The MHRA, Advertising Standards Authority, and the General Pharmaceutical Council have issued a warning to businesses seeking to promote newly authori...

Read More → news_story
Unique liaison programme set to reinforce close collaboration between MHRA and FDA

Unique liaison programme set to reinforce close collaboration between MHRA and FDA

Monday, 15 June 2026

MHRA and FDA liaison programme announced to improve regulatory collaboration and support long-standing international partnership....

Read More → press_release
MHRA scientific leader recognised in 2026 King’s Birthday Honours

MHRA scientific leader recognised in 2026 King’s Birthday Honours

Friday, 12 June 2026

Dr Nicola Rose, Executive Director of Science and Research at the Medicines and Healthcare products Regulatory Agency (MHRA), has been appointed an OB...

Read More → press_release
Lower dose needle free allergy treatment approved for younger children

Lower dose needle free allergy treatment approved for younger children

Friday, 12 June 2026

As with any medicine, the MHRA will keep the safety and effectiveness of the adrenaline nasal spray under close review.??...

Read More → press_release
First GLP 1 tablet for weight loss approved in the UK

First GLP 1 tablet for weight loss approved in the UK

Thursday, 11 June 2026

Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and ...

Read More → press_release
MHRA landmark report reveals public views on AI in healthcare

MHRA landmark report reveals public views on AI in healthcare

Thursday, 11 June 2026

The MHRA is publishing the results of an extensive public consultation which will inform the recommendations of the AI Commission and future regulatio...

Read More → news_story
Pioneering AI health innovations regulatory sandbox launched

Pioneering AI health innovations regulatory sandbox launched

Wednesday, 10 June 2026

The London sandbox is a secure environment designed to safely test AI-enabled devices in a real-world environment so patients can benefit more quickly...

Read More → press_release
MHRA launches AI sandbox to accelerate medicines development and improve safety

MHRA launches AI sandbox to accelerate medicines development and improve safety

Tuesday, 09 June 2026

New AI sandbox will help make medicines safer, speed up development, and reduce reliance on animal testing....

Read More → press_release
Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis

Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis

Tuesday, 09 June 2026

As with all medicines, the MHRA will keep the safety and effectiveness of Nipolcalimab under close review....

Read More → press_release
MHRA review of the benefits and risks of avacopan

MHRA review of the benefits and risks of avacopan

Friday, 05 June 2026

Avacopan is used in the treatment of some rare autoimmune diseases affecting small blood vessels. ...

Read More → news_story
Adjuvanted trivalent influenza vaccine?authorised for adults aged 50 and over

Adjuvanted trivalent influenza vaccine?authorised for adults aged 50 and over

Thursday, 04 June 2026

The adjuvanted trivalent influenza vaccine works by stimulating the immune system to produce its own protection against flu....

Read More → press_release
Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction associated steatohepatitis (MASH) in adults

Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction associated steatohepatitis (MASH) in adults

Wednesday, 03 June 2026

Resmetirom is used in?adults who have experienced inflammation and cell damage, resulting in scarring....

Read More → press_release
Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines 

Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines 

Friday, 29 May 2026

The raid on a Northamptonshire estate dismantled what is believed to be a major illicit manufacturing and distribution operation...

Read More → press_release
Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient 

Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient 

Friday, 29 May 2026

As with any medicine, the MHRA will keep the safety and effectiveness of rilzabrutinib under close review. ...

Read More → press_release
Precautionary recall of blood pressure medication (Crescent Pharma Limited Ramipril 2.5mg capsules) after packaging error

Precautionary recall of blood pressure medication (Crescent Pharma Limited Ramipril 2.5mg capsules) after packaging error

Thursday, 28 May 2026

Patients taking Crescent Pharma Limited Ramipril 2.5mg capsules are advised to check their packaging for batch number GR155023 and contact their pharm...

Read More → press_release
MHRA welcomes Jason Bonander as he starts his role as Chief Digital and Technology Officer

MHRA welcomes Jason Bonander as he starts his role as Chief Digital and Technology Officer

Wednesday, 27 May 2026

Jason is an experienced technology leader with over 25 years working in tech leadership and health informatics. ...

Read More → news_story
Don’t let this heatwave affect your medicines: Three important tips from the MHRA

Don’t let this heatwave affect your medicines: Three important tips from the MHRA

Tuesday, 26 May 2026

Essential advice on protecting your medicines during extreme heat and staying safe. ...

Read More → news_story
Landmark new plans bring treatments for rare diseases a step closer

Landmark new plans bring treatments for rare diseases a step closer

Wednesday, 20 May 2026

The MHRA launches public consultation on new framework that could lead to earlier licensing for therapies for up to 3.5 million people in the UK....

Read More → press_release
MHRA consults on new regulatory framework to make UK a global leader in rare disease therapy development 

MHRA consults on new regulatory framework to make UK a global leader in rare disease therapy development 

Wednesday, 20 May 2026

Proposed Rare Disease Therapies Framework introduces Investigational Marketing Authorisation and compressed development pathways – industry urged to r...

Read More → press_release

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: